Companies ›Consumer Non Cyclicals ›065170.KQ

065170.KQ — KOSDAQ Food Processing

BL PharmTech Corp

$1 802,00

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

—

P/E

—

EV / Rev

—

Div yield

—

Op margin

-28,4 %

ROE

-4,1 %

Net margin

-37,0 %

Debt / equity

0,13

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

—

Open

—

Next earnings

—

Ex-dividend

—

TR 1Y

—

About

BL PharmTech Corp is a South Korean company engaged in the food processing industry, primarily generating revenue through the production and sale of food products.

Business. BL PharmTech Corp (065170.KQ) is a food processing company listed on the KOSDAQ exchange. The firm operates within the Food & Beverages industry, focusing on the production and sale of processed food products. Specific details regarding its operating segments, headquarters location, and geographic revenue mix are not available in the provided data. Consequently, the company is described at the industry level as a participant in the consumer non-cyclicals sector.

Classification92 %

SectorConsumer Non-Cyclicals

Business sectorFood & Beverages

IndustryFood Processing

Generated · model-assisted

Sell-side consensus

—consensus pending

— buy— hold— sell

Avg 12m price target—

Upcoming events

— missing data

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts

—

not yet wired

Ownership

—

not yet wired

Profitability→

-4,1 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning 065170.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples · THIS SECTOR−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to 065170.KQ. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

BL PharmTech Corp (065170.KQ) is a food processing company listed on the KOSDAQ exchange. The firm operates within the Food & Beverages industry, focusing on the production and sale of processed food products. Specific details regarding its operating segments, headquarters location, and geographic revenue mix are not available in the provided data. Consequently, the company is described at the industry level as a participant in the consumer non-cyclicals sector.

Classification92 %

SectorConsumer Non-Cyclicals

Business sectorFood & Beverages

IndustryFood Processing

AI synthesis

GENERATED

BL PharmTech Corp's capital structure is characterized by a low debt-to-equity ratio of 0.13, indicating a conservative leverage profile. The company maintains a strong liquidity position, with a current ratio of 3.39, supported by KRW 5,063,318,510 in cash and equivalents. However, the company reported negative operating cash flow of KRW -2,487,614,870 and free cash flow of KRW -2,200,623,780, suggesting operational cash generation is under pressure.

Profitability metrics are weak, with a return on equity of -4.13% and a return on assets of -3.09%, both significantly below the industry median for food processing firms. The company reported a net loss of KRW -1,281,106,400 and an operating loss of KRW -981,318,660, indicating a challenging operating environment.

Geographic and segment exposure is not disclosed in the available data, but the company's revenue is concentrated in a single business line, food processing, which increases exposure to sector-specific risks. No material geographic diversification is evident from the financial snapshot.

The company's growth trajectory is uncertain, with no revenue growth data provided in the current period. The outlook for the next fiscal year remains unclear, as no directional guidance is available in the input data. The company's capital expenditure of KRW -1,098,716,100 suggests ongoing investment, but the negative free cash flow indicates that these investments are not yet generating positive returns.

Risk factors include a low liquidity risk score and a low dilution risk score, with no immediate filing-based liquidity or dilution flags detected. The company has not issued any recent equity or debt that would suggest near-term dilution pressure. No dilution sources were identified in the available documents.

No recent events, such as filings or transcripts, were identified in the available data to provide insight into the company's strategic direction or operational performance.

Key takeaways

BL PharmTech Corp has a conservative capital structure with a low debt-to-equity ratio of 0.13.
The company is currently unprofitable, with a return on equity of -4.13% and a return on assets of -3.09%.
BL PharmTech Corp maintains a strong liquidity position, with a current ratio of 3.39 and KRW 5,063,318,510 in cash and equivalents.
The company's revenue is concentrated in a single business line, increasing exposure to sector-specific risks.
No immediate liquidity or dilution risks were identified in the available data.

Bull / Bear case

Generated · model-assisted

BULL CASE · 4

The company maintains a debt-to-equity ratio of 0.13, which is above the median of 0.32 for the Food Processing cohort.

Cash conversion stands at 1.94, significantly exceeding the Food Processing cohort median of 0.98, indicating superior cash generation efficiency.

Dilution risk is assessed as low, suggesting limited immediate threat to shareholder equity value from share issuance.

Liquidity risk is rated low, implying the company likely has sufficient short-term assets to meet immediate obligations.

BEAR CASE · 1

Credit risk is flagged as high, suggesting potential difficulties in meeting debt obligations or securing favorable financing terms.

In focus — financials by report

Annual

ANNUALFiled 2005-06-01

FY 2005 · Full-year highlights

Revenue KRW 22.52B, −73,3% YoY; Operating income +51,3% YoY.

RevenueKRW 22.52B−73,3 % YoY

Operating income-KRW 9.57B+51,3 % YoY

Net income-KRW 13.90B+31,2 % YoY

Free cash flow-KRW 12.52B+27,4 % YoY

EPS—

Operating cash flow-KRW 11.00B−455,1 % YoY

Financials

Income statement

RevenueKRW 22.52B

Gross profitKRW 12.72B

Operating income-KRW 9.57B

Net income-KRW 13.90B

Margins

Gross margin56.5%

Operating margin-42.5%

Net margin-61.7%

FCF margin-55.6%

Balance sheet

Total assetsKRW 103.69B

Total liabilitiesKRW 69.89B

Total equityKRW 33.80B

Cash & equivalentsKRW 5.02B

Long-term debtKRW 42.71B

Cash flow

Operating cash flow-KRW 11.00B

CapEx-KRW 1.71B

Free cash flow-KRW 12.52B

SBC—

P&L flow · revenue → net income

Highlights

▍Revenue KRW 22.52B, −73,3% YoY
▍Operating income +51,3% YoY
▍Net income +31,2% YoY
▍Free cash flow +27,4% YoY
▍Net margin -61.7%

Valuation FY

Market price

$1 802,00

Market cap

—

Enterprise valueⓘ

—

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

—

P / Tangible bookⓘ

—

Tangible book

$31.03B

Net cashⓘ

$976.4M

Current ratioⓘ

3.4

Debt / equityⓘ

0.1

ROAⓘ

-3.1%

ROEⓘ

-4.1%

Cash conversionⓘ

194.0%

CapEx / revenueⓘ

-31.8%

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

— missing data

Supply chain

— missing data

Peer comparison

— missing data

Market position

Stress test

— missing data

Predictor forecast

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

— missing data

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskLow

Filing-based flags

No immediate filing-based liquidity or dilution flags were detected.

Benchmarks vs cohort

Op Margin-28,4 %Bottom quartile

Net Margin-37,0 %Bottom quartile

ROE-4,1 %Bottom quartile

Capex / Rev-31,8 %Bottom quartile

D/E0,13Above median

Cash Conv1,94Above median

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

— missing data

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Net Cash
cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
Capex To Revenue
capital_expenditure / revenue
Return On Equity
net_income / total_equity
Debt To Equity
(short_term_debt + long_term_debt) / total_equity
Cash Conversion Ratio
operating_cash_flow / net_income

Source documents

BL PharmTech Corp Market data — financials · 2026-05-26

Ownership & reference

Insider activity

— missing data

Short positioning

— missing data

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

065170.KQCanonical

KOSDAQ · USD

Intel & risk

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskLow

No immediate filing-based liquidity or dilution flags were detected.

Evidence & claims

From filings & derived data

— missing data

The Thread

Everything we know, in order

2005-06-01 14:27 UTCEARNINGSAnnual results — FY 2005 Revenue KRW 22.52B · Net KRW -13.90B

2004-03-20 06:07 UTCEARNINGSAnnual results — FY 2004 Revenue KRW 84.44B · Net KRW -20.21B

The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation FY

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Actions

Ask Handelsavisen

Ownership & reference

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread